Analytical Data
-
Gene name
FAM84A
- Application
-
Alternative Names
FAM84A；FAM84A；NSE1；XAP5;Protein LRATD1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96KN4
-
Expression Region
1-292aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSMGNQLDR ITHLNYSELP TGDPSGIEKD ELRVGVAYFF SDDEEDLDER GQPDKFGVKA PPGCTPCPES PSRHHHHLLH QLVLNETQFS AFRGQECIFS KVSGGPQGAD LSVYAVTALP ALCEPGDLLE LLWLQPAPEP PAPAPHWAVY VGGGQIIHLH QGEIRQDSLY EAGAANVGRV VNSWYRYRPL VAELVVQNAC GHLGLKSEEI CWTNSESFAA WCRFGKREFK AGGEVPAGTQ PPQQQYYLKV HLGENKVHTA RFHSLEDLIR EKRRIDASGR LRVLQELADL VDDKE
-
Molecular Weight
35 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FAM84A (Family with Sequence Similarity 84 Member A) is a protein that has recently garnered attention in cancer research due to its potential role in tumorigenesis and metastasis. Initially identified through genomic studies linking its expression to various cancers, FAM84A is believed to interact with key signaling pathways that regulate cell proliferation, survival, and motility. Research indicates that its overexpression correlates with poor prognosis in several malignancies, including breast, colorectal, and lung cancers. The mechanism underlying FAM84A's role in cancer progression suggests that it may influence the epithelial-to-mesenchymal transition (EMT) and other processes related to cell invasion and metastasis. Recombinant protein studies of FAM84A have facilitated the exploration of its biological functions, such as its involvement in protein-protein interactions and signaling cascades. Through these studies, researchers aim to elucidate the precise molecular mechanisms by which FAM84A contributes to cancer development, with the hope that targeting this protein could lead to novel therapeutic strategies. Additionally, understanding FAM84A's role in normal cellular processes may reveal further insights into its dysregulation in cancer, presenting exciting avenues for future research. Ultimately, FAM84A stands as a promising candidate for biomarker development and a potential therapeutic target in oncology.
